Zynteglo

Bluebird bio Inc (NASDAQ: BLUE) held its Analyst Day in New York last week, and at least one analyst came away less bullish on the stock. The Analyst Wedbush's David Nierengarten downgraded bluebird bio from Outperform to Neutral and reduced his price target from $166 to $131. The Thesis The...